Mario E. Lacouture, MD, discusses the psychosocial impact of dermatologic adverse events from novel therapies in melanoma.
Mario E. Lacouture, MD, dermatologist, Memorial Sloan Kettering Cancer Center, discusses the psychosocial impact of dermatologic adverse events from novel therapies in melanoma.
This impact has been demonstrated in questionnaires from several studies. Lacouture says he has encountered patients who are not willing to go to work because they do not want to disclose that an acneiform rash is from treatment for melanoma. Lacouture has also seen patients who have been unable to sleep because of rash or pruritus.
Finally, he says that both physicians and nurses need to focus on helping their patients live better as well as longer.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo
2 Clarke Drive
Cranbury, NJ 08512